D-Crypt for COVID 19
COVID-19 Vaccine Candidate
Premas Biotech specializes __ developing recombinant proteins for _______ development. Such proteins are _____ “difficult to express proteins” (___-__). Our innovative D-Crypt platform __ optimized for high-yield production __ DTE-Ps, singularly, or in ___________.
Through a partnership ____ Akers Biosciences, Premas is __________ D-Crypt to develop a ______________ recombinant protein vaccine against _____-19.
How does it work?
Immune cells are _________ to identify and destroy __________ agents by recognizing proteins __ the surface of a _____ or bacteria. COVID-19 has _____ surface proteins that are _________ vaccine candidates, the Spike _______, the Envelope Protein, and ___ Membrane protein. An ideal _____-19 vaccine candidate would target ____ than one antigen. The _-_____ platform allows the expression __ each of these proteins ____________ or collectively, in different ____________. The ability to express _____ of the major COVID-19 _______ antigens simultaneously improves the __________ of generating an efficacious _______.
Our deep experience in __________ multi-component vaccines.
Premas has developed ____ 25 vaccine candidates for _____ and animal use, including _________, viral,
anti-helminthic, and ScFV _____ vaccines.
The D-Crypt platform ___ previously scaled multi-component protein _______ successfully and applied
them __ vaccine development. Our platform __ the only example to ____ expressed more than 30 _________
type 1 membrane proteins, _________ the Influenza virus NA _______ and the Rotavirus spike _______. Our
success in expressing ___ large, complex NA protein, _____ us confidence that we ___ produce the
COVID-19 type 1 membrane proteins successfully.
Advantages of the Premas ________
- + Recombinant protein vaccines ___ a well-established method of _______ development and are known __ __ very safe.
- + Highly scalable processes ________ to vaccine candidate strategies _____ on RNA or DNA, ________ a faster development process.
- + The D-Crypt platform ____ a yeast expression host, _____ has GRAS (“generally recommended __ safe”) status granted by the _____, expediting regulatory approval.
- + The Premas team __ highly skilled in developing _____-_________ recombinant protein vaccine candidates. We _______ from a 20k square ____ facility, which is ISO9001:2015 _________, and GMP compliant.
- + Premas is capable __ process development, scaling up, ___ production of proteins and ___ developed more than 650 specialized ________ for our global partners.
